The combination of STING agonists with ICIs (PD-1 inhibitor or CTLA-4 antibody) has presented significant synergistic anti-tumor effects in several tumor models, and the clinical efficacy of STING agonists integrated with PD-1 antibody is under investigation in patients for cancer immunotherapy. This evidence concerns the gene STING1 and cancer.